Updates

July 9, 2020July 9, 2020
Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

YourVaccx, a new type of cancer vaccine developed by ImmunSYS, is safe and shows promising effectiveness in patients with metastatic prostate cancer and other ... Read more
June 30, 2020June 30, 2020
FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported ... Read more
June 30, 2020June 30, 2020
Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study

Adding ipatasertib to standard treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly extended survival without disease worsening in a group of men whose tumors lack ... Read more
June 25, 2020June 25, 2020
Relugolix Granted FDA Priority Review as New Treatment Type

The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) Myovant Sciences submitted earlier this year requesting ... Read more
June 23, 2020June 23, 2020
Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC

The U.S. rates of advanced prostate cancer continued to rise in men 50 and older after the U.S. Preventive Services Task Force (USPSTF) ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European ... Read more

Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study

Relugolix Granted FDA Priority Review as New Treatment Type

Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC

Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial

Cancer DNA Levels in Blood Can Predict Treatment Responses

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population

NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic

ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests

Subscribe to our mailing list

Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients

Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

FDA Approves Lynparza for mCRPC Patients with Mutations in DNA Repair Genes

Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

Gene Variant Seen to Promote Castration-resistant Disease in Whites

Winners Named for Prostate Cancer Foundation’s TRUE Love Awareness Contest

Guidelines for Radiation Therapy with COVID-19 Urge Less Treatment

Combining Two Biopsy Methods Improves PC Diagnosis, Study Shows

Urine Biomarkers Can Be Used to Develop Test for Prostate Cancer, Study Finds

Proscia and UCSF Partnering to Deliver AI Apps to Improve Cancer Diagnosis

Veru Advances Prostate Cancer Therapy VERU-111 to Phase 2 Portion of Trial

Adoptive Cell Therapy Can Slow Prostate Cancer Growth, Study in Mice Reports

Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show

Prolaris Test Predicts Which PC Patients Benefit from Combo Therapy, Study Finds

3 New miR Scientific Urine Tests Diagnose, Classify Prostate Cancer, Data Shows

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery

Statins, Metformin May Extend Survival in High-risk Prostate Cancer, Large Study Suggests

Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows

High Vegetable Diet Does Not Halt Prostate Cancer, Study Finds

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest

UPenn Researchers Awarded $500K Grant to Develop CAR T-cell Therapy for Advanced PC

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

Pin It on Pinterest